Total Valuation
Eikon Therapeutics, Inc. has a market cap or net worth of $484.78M. The enterprise value is $427.28.
Market Cap$484.78M
Enterprise Value$427.28
Share Statistics
Eikon Therapeutics, Inc. has 54,165,030 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding54,165,030
Owned by Insiders22.48%
Owned by Institutions20.21%
Financial Efficiency
Eikon Therapeutics, Inc.’s return on equity (ROE) is 0.37 and return on invested capital (ROIC) is -61.65%.
Return on Equity (ROE)0.37
Return on Assets (ROA)-0.55
Return on Invested Capital (ROIC)-61.65%
Return on Capital Employed (ROCE)-0.63
Revenue Per Employee0.00
Profits Per Employee-844.40K
Employee Count384
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Eikon Therapeutics, Inc. is ―. Eikon Therapeutics, Inc.’s PEG ratio is 0.00.
PE Ratio―
PS Ratio0.00
PB Ratio-0.92
Price to Fair Value-0.92
Price to FCF-3.45
Price to Operating Cash Flow-1.89
PEG Ratio0.00
Income Statement
In the last 12 months, Eikon Therapeutics, Inc. had revenue of 0.00 and earned -324.25M in profits. Earnings per share was -6.16.
Revenue0.00
Gross Profit-24.18M
Operating Income-338.94M
Pretax Income-324.25M
Net Income-324.25M
EBITDA-299.24M
Earnings Per Share (EPS)-6.16
Cash Flow
In the last 12 months, operating cash flow was -256.02M and capital expenditures -3.18M, giving a free cash flow of -259.20M billion.
Operating Cash Flow-256.02M
Free Cash Flow-259.20M
Free Cash Flow per Share-4.79
Dividends & Yields
Eikon Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.01
52-Week Price Change-40.33%
50-Day Moving Average10.15
200-Day Moving Average―
Relative Strength Index (RSI)40.78
Average Volume (3m)546.05K
Important Dates
Eikon Therapeutics, Inc. upcoming earnings date is Aug 13, 2026, Before Open (Confirmed).
Last Earnings DateMay 11, 2026
Next Earnings DateAug 13, 2026
Ex-Dividend Date―
Financial Position
Eikon Therapeutics, Inc. as a current ratio of 6.34, with Debt / Equity ratio of 54.07%
Current Ratio6.34
Quick Ratio6.34
Debt to Market Cap0.00
Net Debt to EBITDA-0.51
Interest Coverage Ratio-404.95
Taxes
In the past 12 months, Eikon Therapeutics, Inc. has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Eikon Therapeutics, Inc. EV to EBITDA ratio is -3.22, with an EV/FCF ratio of -4.10.
EV to Sales0.00
EV to EBITDA-3.22
EV to Free Cash Flow-4.10
EV to Operating Cash Flow-5.12
Balance Sheet
Eikon Therapeutics, Inc. has $531.58M in cash and marketable securities with $252.22M in debt, giving a net cash position of $279.36M billion.
Cash & Marketable Securities$531.58M
Total Debt$252.22M
Net Cash$279.36M
Net Cash Per Share$5.16
Tangible Book Value Per Share-$16.24
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Eikon Therapeutics, Inc. is $30.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$30.50
Price Target Upside178.28% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast―